Pharmaceutical Technology

MARCH 1, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The drug candidate targets DNA-dependent protein kinase (DNA-PK). The drug candidate is administered through the oral route in the form of capsule and tablet.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Drug Discovery World

DECEMBER 8, 2023

The news highlights this week are mostly focused around neuroscience, with new guiding principles and a drug repurposing fund launched for motor neuron disease research, a new drug target found for early-onset dementia, and a possibly game-changing schizophrenia drug entering human trials.

Drugs 52

Drugs DNA Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 23, 2020

Additionally, Phase 1 clinical data found INO-4800 to have a favorable safety and tolerability profile with no serious adverse events reported; only six Grade 1 adverse events (AEs) were observed, primarily minor injection site reactions. . ” Findings from the Phase 1 Clinical Trial.

DNA 40

DNA Vaccination Vaccine Immune Response 40

Drug Discovery World

APRIL 30, 2024

Its job is to carry coding information that is essential to the translation and processing of functional proteins. This is essential to its use as a therapeutic agent and gives the technology a vast versatility making it suitable to treating a wide range of diseases – especially those that have high protein expression.

RNA 52

RNA Protein Vaccination Vaccine 52

The Pharma Data

MARCH 30, 2021

Basel, March 30, 2021 — Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc.

Protein 52

Protein Licensing Licensing Containment 52

Drug Discovery World

AUGUST 2, 2023

Cancer cells unable to copy their DNA One of the ways PARP inhibitors work in cancer cells with changes in their BRCA genes is by preventing them from repairing their DNA, leading to a build-up of damage and causing the cells to die. Without CINP, cancer cells aren’t able to properly copy their DNA when treated with the drug.

Gene 52

Gene DNA Clinical Trials Clinical Trials 52

Drug Discovery World

OCTOBER 20, 2023

Its proprietary technology, Proximity Extension Assay (PEA), provides high throughput protein analysis. Through the purchase, Thermo Fisher will also gain a library of more than 5,300 validated protein biomarker targets. BioCina will provide process development and GMP manufacturing for Minicircle DNA and Plasmid DNA.

Drugs 52

Drugs Antibody DNA Gene Therapy 52

Camargo

JULY 27, 2021

It is a comprehensive term which encompasses a large variety of therapy products including viral and bacterial vectors, plasmid DNA, human gene editing technology, and patient-specific cellular gene therapy. Additionally, gene editing allows us either to remove or to modify harmful genes. Formulation Considerations.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

Drug Discovery World

JULY 17, 2023

This protein is the primary sensor of cytosolic double-stranded DNA (dsDNA), and when dysfunctional, is involved in toxic neuroimmune responses to tau tangles. IRBM’s Chief Science Officer Carlo Toniatti said: “Together, we aim to bring a wealth of first-in-class, pre-clinical assets into clinical trials to improve patient outcomes.

Protein 52

Protein DNA Clinical Trials Clinical Trials 52

Roots Analysis

FEBRUARY 27, 2024

Currently, product licensing agreements, technology licensing agreements, research and development agreements and clinical trial agreements are the common types of partnerships inked by developers that are currently focused on the development of ADCs pipeline. In nature, they are made by a group of bacteria known as actinomycetes.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

Scienmag

MARCH 15, 2021

The first vaccine has been administered in a comparative adjuvant trial of DNA prime/protein boost HIV vaccine regimens in Kericho, Kenya Credit: U.S. Military HIV Research Program SILVER SPRING, Md.

Vaccination 68

Vaccination Vaccine Trials DNA 68

Drug Discovery World

JANUARY 17, 2024

Brett Swansiger, Chief Commercial Officer at ANGLE discusses the importance of liquid biopsies in precision medicine trials for cancer. Furthermore, oncology clinical trials are frequently challenged by low enrolment rates, failure to achieve primary endpoints, study design complexity and limited funding 5.

Medicine 57

Medicine DNA Genome Genomics 57

Drug Discovery World

OCTOBER 18, 2023

4 Unfortunately, many AAV-based gene therapies fail during clinical trials, despite them appearing safe and efficacious in preclinical studies. Consequently, researchers are progressing treatments that are unlikely to succeed at clinical trials, while rejecting potentially powerful ones.

Gene Therapy 62

Gene Therapy Gene Clinical Trials Clinical Trials 62

Bioengineer

JANUARY 16, 2024

This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP binding site, overcoming resistance mechanisms. Reported changes include L718Q and L718V.

Genome 119

Genome Genomics Protein In-Vitro 119

Drug Discovery World

NOVEMBER 30, 2023

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK. GSK has developed high-throughput mammalian and E.

Antibody 57

Antibody Protein Engineer In-Vivo 57

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. The FDA’s endorsement of Sunlenca is backed by compelling clinical evidence, demonstrating its efficacy as a viable treatment option.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

pharmaphorum

JANUARY 10, 2023

The alliance has also yielded a computer vision system to improve the accuracy and speed of immune response evaluations, and a platform that has improved the success rate and throughput of DNA/RNA synthesis. The post BioNTech buys UK-based AI startup InstaDeep in £562m deal appeared first on.

Vaccination 116

Vaccination Vaccine Clinical Trials Clinical Trials 116

Drug Discovery World

APRIL 5, 2023

The drug, which is now called NXP800 and has already entered a Phase I clinical trial, was discovered by scientists at The Institute of Cancer Research, London. It targets a pathway that cancer cells are highly dependent upon, involving the heat shock factor 1 protein (HSF1).

Drugs 52

Drugs Scientist Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 3, 2021

Food and Drug Administration (FDA) has determined that OAV-101 intrathecal (IT) clinical trials for spinal muscular atrophy (SMA) patients may proceed, thereby lifting the partial clinical trial hold initiated in October 2019. Novartis today announced that the U.S. SVP, Chief Medical Officer, Novartis Gene Therapies. “We

Clinical Trials 52

Clinical Trials Clinical Trials Gene Therapy Trials 52

Drug Discovery World

DECEMBER 15, 2022

These platforms all induce double strand cuts in the chromosomal DNA that can be sealed by the cell, leading to a specific gene disruption, or resulting in a new target site for inserting DNA segments. Early phase clinical trials for gene editing therapies. Gene editing challenges and potential solutions.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Drug Discovery World

AUGUST 16, 2023

Additionally, patients whose cancer has spread but who have not yet received chemotherapy, and whose primary tumours have markers of faults in genes linked to DNA repair pathways, tend to respond better to carboplatin. “Our findings paint a complex picture – with many, dynamic factors driving how tumours respond to treatment.”

Genetics 52

Genetics Gene Hormones RNA 52

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. These methods offer safer CAR T-based therapies, laying the foundation for clinical trials and the rapid development of a new generation of CAR T cells for both autologous and allogeneic use.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

OCTOBER 11, 2022

The team developed a way to transform the Cas-9 protein into a spherical nucleic acid (SNA) and load it with critical components to access a broad range of tissue and cell types. They created a system to deliver the cargo required for generating the gene editing machine known as CRISPR-Cas9. High gene editing efficiency.

Gene Editing 52

Gene Editing Gene DNA Protein 52

Drug Discovery World

APRIL 8, 2024

Following this, Benjamin Cravatt, Professor and the Norton Gilula Chair in Biology and Chemistry at The Scripps Research Institute, discussed activity-based protein profiling (ABPP) and its use in discovering drug candidates for cancer-relevant proteins.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

XTalks

MARCH 13, 2024

XTALKS WEBINAR: Addressing Ophthalmology Clinical Trial Design and Effective Data Monitoring Committee Strategies On-Demand: Thursday, February 8, 2024 Register for this free webinar gain insights into statistical data strategies for ophthalmology clinical trials and learn best practices for establishing and reporting ophthalmic data.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

XTalks

DECEMBER 27, 2022

Boorjian, MD, Carl Rosen Professor and Chair of the Department of Urology at Mayo Clinic, and lead investigator on the recent clinical trial of Adstiladrin, in the company’s press release. Then, the cells translate the DNA sequence of the gene and secrete high amounts of the protein interferon alfa-2b.

Gene Therapy 52

Gene Therapy FDA Approval Gene Clinical Trials 52

XTalks

SEPTEMBER 2, 2021

The AlzoSure Predict prognostic biomarker Alzheimer’s blood test detects levels of an unfolded conformational variant of the p53 protein in the blood using a proprietary antibody called U-p53AZ. It is known as the “guardian of the genome” given its central role in the DNA damage response. p53 in Alzheimer’s.

Protein 105

Protein DNA Antibody Genome 105

Drug Discovery World

DECEMBER 13, 2022

The genetic anomaly blocks the chemical glycosylation of a biologically important protein. Using an experimental technique called exon skipping by antisense oligonucleotides, the team corrected a mistake in the FKTN gene that blocks the chemical glycosylation of a biologically important protein. .

RNA 52

RNA Genetics Gene In-Vitro 52

pharmaphorum

OCTOBER 31, 2022

The small-molecule PIKfyve inhibitor – called VRG50635 – has been administered to the first subject in the phase 1 trial involving healthy volunteers, according to the San Francisco-based biotech, which was founded in 2015 by Alice Zhang and Jason Chen.

Genome 136

Genome Genomics Drugs RNA 136

Find Me Cure

OCTOBER 13, 2019

There currently are drugs that do just that but now they’re in clinical trials for metastatic breast cancer as well. HER2 is a protein that plays an important role in cancer cell growth and is found on the surface of cancer cells in a very high quantity in about 10-20% of breast cancers. Rosenberg, M.D.

Development 52

Development DNA Clinical Trials Clinical Trials 52

XTalks

APRIL 6, 2022

Cancerous cells and tumors release small fragments of DNA into the bloodstream called circulating tumour DNA (ctDNA). The researchers at the Cancer Research UK Cambridge Institute published this data from the LUng cancer CIrculating tumour DNA (LUCID) study in the journal Annals of Oncology.

DNA 105

DNA In-Vitro Doctors Doctor 105

XTalks

DECEMBER 4, 2023

In a statement outlining its investigation, the FDA said it received reports of the T-cell malignancies from clinical trials and post-marketing safety monitoring. The vectors can potentially cause cancer by inserting genetic material into a patient’s genome, particularly near cancer-related DNA sequences or suppressors​​​​.

Gene Therapy 69

Gene Therapy Gene Clinical Trials Clinical Trials 69

Drug Discovery World

JANUARY 21, 2024

It is enabling computational protein design for vaccine immunogen discovery, and high-throughput and high-definition assays for quicker and more comprehensive characterisation of vaccine candidates and vaccine-elicited immunity. His recent research focuses on vaccines against influenza and other (re)emerging viruses.

Protein 52

Protein Vaccination Vaccine Development 52

Drug Discovery World

OCTOBER 6, 2022

In the cancer space alone over the last five years, clinical trials have increased 500% for new drugs and new drug combinations. Identifying the population subsets who will benefit is essential to the success of these therapies in both the clinic and in the clinical trials that will bring these drugs to market. .

Medicine 52

Medicine Clinical Trials Clinical Trials Genome 52

Drug Discovery World

MARCH 6, 2024

Mutations in a gene may cause structural changes in its protein product, which can lead to a loss of function and consequently to the onset of a disease. The fact that 100+ clinical trials in Alzheimer’s have failed to demonstrate clinical efficacy should warn us that this is too simplistic an approach in neurological diseases.

Genome 62

Genome Genomics Clinical Trials Clinical Trials 62

Drug Discovery World

APRIL 11, 2024

Treatment of BRCA2-deficient but not wild-type DLD1 cells with BSM-1516 resulted in cell cycle arrest accompanied by DNA damage signalling and accumulation of chromatin-bound RPA32, a marker of ssDNA. LAE119 is a potent and selective PARP1 inhibitor and PARP1-DNA trapper.

HR 52

HR Antibody In-Vitro DNA 52

Drug Discovery World

AUGUST 2, 2022

This approach uses molecules that can rewrite the single mutations that are buried within the DNA of heart cells in people with genetic cardiomyopathies. . We believe that we will have a gene therapy ready to start testing in clinical trials in the next five years. .

Gene Editing 52

Gene Editing Gene Research Genetics 52